

Highlights of This Issue 2639

THERAPEUTIC DISCOVERY

- 2641 **Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody**
Angela Coxon, James Bready, Hosung Min, Stephen Kaufman, Juan Leal, Dongyin Yu, Tani Ann Lee, Ji-Rong Sun, Juan Estrada, Brad Bolon, James McCabe, Ling Wang, Karen Rex, Sean Caenepeel, Paul Hughes, David Corlover, Haejin Kim, Seog Joon Han, Mark L. Michaels, Eric Hsu, Grant Shimamoto, Russell Cattley, Eunju Hurh, Linh Nguyen, Shao Xiong Wang, Anthony Ndifor, Isaac J. Hayward, Beverly L. Falcón, Donald M. McDonald, Luke Li, Tom Boone, Richard Kendall, Robert Radinsky, and Jonathan D. Oliner
- 2652 **Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer**
Elizabeth Buck, Prafulla C. Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre, Nianjun Tao, Maryland Rosenfeld-Franklin, Lorena Lerner, M. Isabel Chiu, Robert Wild, David Epstein, Jonathan A. Pachter, and Mark R. Miglarese
- 2665 **Curcumin Enhances the Effect of Cisplatin in Suppression of Head and Neck Squamous Cell Carcinoma via Inhibition of IKK β Protein of the NF κ B Pathway**
Victor M. Duarte, Eugene Han, Mysore S. Veena, Amanda Salvado, Jeffrey D. Suh, Li-Jung Liang, Kym F. Faull, Eri S. Srivatsan, and Marilene B. Wang
- 2676 **Small Interfering RNA Targeting 14-3-3 ζ Increases Efficacy of Chemotherapeutic Agents in Head and Neck Cancer Cells**
Ajay Matta, Leroy V. DeSouza, Ranju Ralhan, and K.W. Michael Siu

- 2689 **Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules**
Manu Lopus, Emin Oroudjev, Leslie Wilson, Sharon Wilhelm, Wayne Widdison, Ravi Chari, and Mary Ann Jordan
- 2700 **Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability**
Emin Oroudjev, Manu Lopus, Leslie Wilson, Charlene Audette, Carmela Provenzano, Hans Erickson, Yelena Kovtun, Ravi Chari, and Mary Ann Jordan
- 2714 **The Use of One-Bead One-Compound Combinatorial Library Technology to Discover High-Affinity $\alpha\beta$ 3 Integrin and Cancer Targeting Arginine-Glycine-Aspartic Acid Ligands with a Built-in Handle**
Wenwu Xiao, Yan Wang, Edmond Y. Lau, Juntao Luo, Nianhuan Yao, Changying Shi, Leah Meza, Harry Tseng, Yoshiko Maeda, Pappanaicken Kumaresan, Ruiwu Liu, Felice C. Lightstone, Yoshikazu Takada, and Kit S. Lam
- 2724 **Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment**
Hongyan Xiao, Qingbei Zhang, Jikun Shen, Vytautas Bindokas, and H. Rosie Xing

PRECLINICAL DEVELOPMENT

- 2737 **Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy *In vivo* in Human Acute Myeloid Leukemia Models**
Deepika Lal, Jennifer A. Park, Kellie Demock, Joseph Marinaro, Amanda M. Perez, Mei-Hui Lin, Lili Tian, Terry J. Mashtare, Michael Murphy, Joshua Prey, Meir Wetzler, Gerald J. Fetterly, and Eunice S. Wang

- 2752 **Monitoring Molecular-Specific Pharmacodynamics of Rapamycin *In vivo* with Inducible *Gal4*→*Fluc* Transgenic Reporter Mice**
Mei-Hsiu Pan, Jeffrey Lin, Julie L. Prior, and David Piwnica-Worms
- 2761 **Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma**
Gerd R. Silberhumer, Peter Brader, Joyce Wong, Inna S. Serganova, Mithat Gönen, Segundo Jaime Gonzalez, Ronald Blasberg, Dmitriy Zamarin, and Yuman Fong
- 2770 **Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer**
David Luyimbazi, Argun Akcakanat, Priscilla F. McAuliffe, Li Zhang, Gopal Singh, Ana Maria Gonzalez-Angulo, Huiqin Chen, Kim-Anh Do, Yuhuan Zheng, Mien-Chie Hung, Gordon B. Mills, and Funda Meric-Bernstam
- 2785 **TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an *EGFR* Mutation**
Wataru Okamoto, Isamu Okamoto, Kaoru Tanaka, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Haruka Yamaguchi, Tokuzo Arao, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, and Kazuhiko Nakagawa
- 2793 **Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling**
Rupal S. Bhatt, Xiaoen Wang, Liang Zhang, Michael P. Collins, Sabina Signoretti, David C. Alsop, S. Nahum Goldberg, Michael B. Atkins, and James W. Mier
- 2803 **Association of Human Cytochrome P450 1A1 (*CYP1A1*) and Sulfotransferase 1A1 (*SULT1A1*) Polymorphisms with Differential Metabolism and Cytotoxicity of Aminoflavone**
Qiang Zheng, Xianyi Sha, Jiansheng Liu, Elisabeth Heath, Patricia LoRusso, and Jing Li
- 2814 **Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context**
Wen-Liang Kuo, Jing Liu, Helena Mauzeri, Everett E. Vokes, Ralph Weichselbaum, Marsha Rich Rosner, and Ezra Eddy Wyssam Cohen

MOLECULAR MEDICINE IN PRACTICE

- 2825 **Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors**
Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, Wataru Okamoto, Masaki Miyazaki, Ryotaro Morinaga, Shinya Ueda, Masaaki Terashima, Asuka Tsuya, Akiko Sarashina, Koichi Konishi, Tokuzo Arao, Kazuto Nishio, Rolf Kaiser, and Kazuhiko Nakagawa
- 2834 **Multigene Expression-Based Predictors for Sensitivity to Vorinostat and Velcade in Non-Small Cell Lung Cancer**
Alykhan S. Nagji, Sang-Hoon Cho, Yuan Liu, Jae K. Lee, and David R. Jones
- 2844 **Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics**
Teresa Macarulla, Andres Cervantes, Elena Elez, Edith Rodríguez-Braun, José Baselga, Susana Roselló, Gemma Sala, Inma Blasco, Hadi Danaee, Yih Lee, Jeffrey Ecsedy, Vaishali Shinde, Arijit Chakravarty, Douglas Bowman, Hua Liu, Omar Eton, Howard Fingert, and Josep Tabernero

LETTERS TO THE EDITOR


- 2853 **A Better TRAIL Variant for Tumor Cell-Specific Targeting? – Letter**
Edwin Bremer and Wijnand Helfrich
- 2854 **A Better TRAIL Variant for Tumor Cell-Specific Targeting? – Response**
Dirk Spitzer, Peter Goedegebuure, and William G. Hawkins

CORRECTIONS

- 2856 **Correction: Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis – Letter**
- 2856 **Correction: Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis Still an Unresolved Question – Response**

ABOUT THE COVER

The antibody-linked maytansinoid DM1 conjugate and its intracellular metabolites bind to microtubule ends and suppress microtubule dynamics with high potency at subnanomolar concentrations, thus arresting mitosis and inhibiting tumor cell proliferation. Using immunofluorescence microscopy, the MCF7 breast cancer cell is shown arrested in an abnormal mitosis after incubation with 340 pmol/L of the metabolite S-methyl DM1 (the concentration that half-maximally arrests mitosis) and exhibits uncongressed chromosomes (blue) located at one of the spindle poles which is marked by anti-pericentrin staining (red). Microtubules are green. For details, see articles by Oroudjev and colleagues on page 2700 and Lopus and colleagues on page 2689.



Molecular Cancer Therapeutics

9 (10)

Mol Cancer Ther 2010;9:2639-2856.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/9/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/9/10>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.